Zug, Switzerland, 1 June 2020 – Arvelle Therapeutics, an emerging biopharmaceutical company focused on bringing innovative treatments to patients suffering from CNS disorders, today announces that Mark Altmeyer, President and Chief Executive Officer of Arvelle, will present at the Jefferies Virtual Healthcare Conference on Thursday, 4 June, at 11:00 a.m. EDT.

A live webcast of the presentation will be available at Arvelle’s website, www.arvelletx.com, under the Events section.

For more information please contact:

Arvelle Therapeutics

Email: Juan.Vergez@arvelletx.com

Head of Marketing and Corporate Communications

Consilium Strategic Communications (international strategic communications)

Mary-Jane Elliott/Susan Stuart/Alex Harrison/Lindsey Neville

Email: arvelletherapeutics@consilium-comms.com

Telephone: +44 (0)20 3709 5700

About Arvelle Therapeutics

Arvelle Therapeutics is an emerging biopharmaceutical company focused on bringing innovative solutions to patients suffering from CNS disorders. Arvelle is responsible for the development and commercialization of cenobamate, an investigational antiepileptic drug, in the European market. Arvelle is headquartered in Switzerland and received start-up financing of $207.8 million, one of the largest initial financing commitments for a European-focused biopharmaceutical company, with investments from a global syndicate including NovaQuest Capital Management, BRV Capital Management, LSP, H.I.G. BioHealth Partners, Andera Partners, F-Prime Capital and KB Investments. More information is available at https://arvelletx.com.